TNF Pharmaceuticals, Inc. (TNFA) Stock Analysis

TNF Pharmaceuticals, Inc. (TNFA) Healthcare & Pipeline Overview

TNF Pharmaceuticals, Inc. is a clinical-stage biotech firm developing MYMD-1, an immune system regulator targeting chronic inflammation and aging, and Supera-CBD, a novel cannabidiol derivative for pain and addiction, positioning them within the evolving pharmaceutical landscape.

What Is the Investment Thesis for TNFA?

TNF Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The company's valuation is influenced by the potential success of its MYMD-1 and Supera-CBD platforms. Key value drivers include the successful completion of clinical trials, regulatory approvals, and subsequent commercialization. The company's small market capitalization of $9.18M reflects its early stage and inherent risks. Upcoming clinical trial results for MYMD-1 and Supera-CBD represent significant catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development.

Based on FMP financials and quantitative analysis

TNFA Key Highlights

TNF Pharmaceuticals, Inc. is a clinical-stage company with no current revenue, making it reliant on future clinical and regulatory success.

• The company's lead drug candidate, MYMD-1, targets TNF-a, a key driver of chronic inflammation, offering potential in autoimmune diseases and aging.
• Supera-CBD, the company's second drug platform, is a novel synthetic CBD derivative aimed at the growing market for pain, addiction, and epilepsy treatments.
• The company's small size, with only two employees, indicates a lean operation but also highlights potential resource constraints.
• TNF Pharmaceuticals, Inc. operates in the high-risk, high-reward biotechnology sector, where clinical trial outcomes and regulatory approvals are critical.

Who Are TNFA's Competitors?

TNFA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TNFA's Key Strengths?

Novel drug platforms targeting unmet medical needs.

• Clinical-stage assets with some clinical data available.
• Potential for partnerships and licensing agreements.
• Focus on treating the underlying causes of diseases.

What Are TNFA's Weaknesses?

Small size and limited resources.

• Reliance on successful clinical trial outcomes.
• Dependence on regulatory approvals.
• Lack of current revenue.

What Could Drive TNFA Stock Higher?

Clinical trial results for MYMD-1 in autoimmune diseases.

• Clinical trial results for Supera-CBD in chronic pain.
• Potential partnerships and licensing agreements with larger pharmaceutical companies.
• Advancing MYMD-1 and Supera-CBD through preclinical and clinical development.

What Are the Key Risks for TNFA?

Financial-distress signal — its Altman Z-Score of -5.42 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-57.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for MYMD-1 and Supera-CBD.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from larger pharmaceutical companies with greater resources.
• Need for additional capital to fund ongoing research and development.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for TNFA?

• TNF Pharmaceuticals, Inc. has the opportunity to capture a share of this market by successfully developing and commercializing MYMD-1. Positive clinical trial results and regulatory approval could drive significant growth. The timeline for commercialization depends on clinical trial progress and regulatory review, potentially within the next 3-5 years.
• MYMD-1 for Aging and Longevity: The market for therapies targeting aging and longevity is emerging, driven by increasing interest in extending healthy lifespans. MYMD-1's potential to regulate the immune system and control chronic inflammation could position it as a valuable asset in this market. The timeline for development and commercialization is uncertain, but initial research and development could begin within the next 1-2 years.
• Supera-CBD for Chronic Pain: The market for chronic pain treatments is large and growing, driven by the opioid crisis and the need for alternative pain management options. Supera-CBD's novel synthetic CBD derivative could offer advantages over existing CBD products, including improved efficacy and safety. Clinical trials and regulatory approval are necessary for commercialization, potentially within the next 3-5 years.
• Supera-CBD for Addiction: The market for addiction treatments is also growing, driven by the opioid epidemic and other substance abuse issues. Supera-CBD's potential to address addiction could position it as a valuable asset in this market. Clinical trials and regulatory approval are necessary for commercialization, potentially within the next 3-5 years.
• Partnerships and Licensing Agreements: TNF Pharmaceuticals, Inc. could pursue partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug platforms. These agreements could provide funding, expertise, and access to established distribution networks. The timeline for securing partnerships and licensing agreements is uncertain, but could occur within the next 1-2 years.

What Are TNFA's Competitive Advantages?

• Proprietary drug platforms: MYMD-1 and Supera-CBD are protected by patents.
• Novel mechanisms of action: MYMD-1 targets TNF-a, a key driver of chronic inflammation, while Supera-CBD is a novel synthetic CBD derivative.
• Clinical-stage assets: MYMD-1 and Supera-CBD have already undergone some clinical testing, providing a head start over competitors.

What Does TNFA Do?

Founded in 2014 and formerly known as MyMD Pharmaceuticals, Inc., TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapeutic platforms. The company focuses on addressing the underlying causes of diseases rather than merely treating symptoms. Their lead drug platform, MYMD-1, is a small molecule designed to regulate the immune system by controlling TNF-a, a key driver of chronic inflammation, and other pro-inflammatory cytokines. MYMD-1 is currently under development for potential applications in delaying aging, increasing longevity, and treating autoimmune diseases. The company's second drug platform, Supera-CBD, is a novel synthetic derivative of cannabidiol (CBD) being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD aims to capitalize on the growing CBD market, which includes both FDA-approved drugs and unregulated CBD products. TNF Pharmaceuticals, Inc. is headquartered in Baltimore, Maryland, and operates with a small team of two employees.

What Products and Services Does TNFA Offer?

• Develop MYMD-1, a drug platform targeting the immune system to control TNF-a and reduce chronic inflammation.
• Develop Supera-CBD, a novel synthetic derivative of cannabidiol (CBD) for treating chronic pain, addiction, and epilepsy.
• Conduct clinical trials to evaluate the safety and efficacy of MYMD-1 and Supera-CBD.
• Seek regulatory approvals from the FDA to market and sell MYMD-1 and Supera-CBD.
• Focus on treating the underlying causes of diseases rather than just addressing the symptoms.
• Target the growing markets for autoimmune disease treatments, pain management, and addiction therapies.

How Does TNFA Make Money?

• Develop and patent novel therapeutic platforms.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA.
• Commercialize approved drugs through direct sales or partnerships.

What Industry Does TNFA Operate In?

TNF Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant investment. The market for autoimmune disease treatments and pain management is substantial and growing, driven by aging populations and increasing prevalence of chronic conditions. Competition is fierce, with numerous companies developing novel therapies. TNF Pharmaceuticals, Inc. aims to differentiate itself through its unique MYMD-1 and Supera-CBD platforms, targeting specific mechanisms of action and addressing unmet medical needs.

Who Are TNFA's Key Customers?

• Patients with autoimmune diseases.
• Patients with chronic pain.
• Patients with addiction.
• Patients with epilepsy.

How TNF Pharmaceuticals, Inc. Is Valued

TNF Pharmaceuticals, Inc. carries a market capitalization of $9.18M, placing it in the micro-cap category.

Company Profile

TNF Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Mitchell Glass. TNFA has traded publicly since 2014.

Return on equity for TNF Pharmaceuticals, Inc. stands at -57.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.7%, showing how much profit it generates from its asset base. A current ratio of 3.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.0%, the inverse of the P/E and a quick read on earnings relative to price.

TNF Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.42 places it in the distress zone, a signal of elevated financial risk.

The most recent 3 insider filings for TNF Pharmaceuticals, Inc. break down as 0 sales and 3 purchases. On net that is roughly 225K shares acquired (about $41K) — insiders putting money in tends to read as conviction.

TNFA Financials

TNFA Latest News

No recent news available for TNFA.

TNF Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources